Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells 24,727 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 24,727 shares of the company’s stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $80.26, for a total transaction of $1,984,589.02. Following the completion of the sale, the chief operating officer directly owned 61,202 shares in the company, valued at $4,912,072.52. This trade represents a 28.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock traded up $4.51 during trading on Wednesday, hitting $78.93. 934,950 shares of the company’s stock were exchanged, compared to its average volume of 769,289. The business has a 50-day simple moving average of $79.80 and a 200-day simple moving average of $70.30. Kymera Therapeutics, Inc. has a 52-week low of $19.44 and a 52-week high of $103.00. The stock has a market capitalization of $6.44 billion, a price-to-earnings ratio of -21.45 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. During the same quarter in the prior year, the firm earned ($0.88) earnings per share. The company’s revenue for the quarter was down 60.8% on a year-over-year basis. On average, equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Leerink Partners upped their target price on Kymera Therapeutics from $70.00 to $118.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Mizuho lifted their price target on Kymera Therapeutics from $81.00 to $120.00 and gave the company an “outperform” rating in a research report on Thursday, December 11th. Citigroup boosted their price target on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, January 22nd. Finally, Barclays raised their price objective on shares of Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $118.90.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Baker BROS. Advisors LP increased its position in shares of Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after buying an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after buying an additional 1,124,747 shares in the last quarter. Vanguard Group Inc. grew its stake in Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after acquiring an additional 845,922 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Kymera Therapeutics by 20.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after acquiring an additional 1,061,957 shares during the period. Finally, BVF Inc. IL increased its holdings in Kymera Therapeutics by 6.6% in the 2nd quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock worth $240,138,000 after acquiring an additional 340,909 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.